Gilead's HIV Medicines

Gilead Sciences is the world's leading developer of HIV medicines. Today, 4.3 million HIV patients worldwide are receiving the company's antiretroviral therapies.[1]

Gilead has played a central role in the simplification of HIV treatment in recent years with a focus on the development of co-formulated single tablet regimens, which provide a complete multi-drug course of therapy in a single, once-daily pill. Single tablet regimens are designed to help HIV patients adhere to a fully suppressive treatment regimen on a consistent basis, which supports positive treatment outcomes.[2] These simplified medicines are preferred by patients and have become a standard of care in HIV therapy today.[3,4] Treatment guidelines issued by the European AIDS Clinical Society recommend several of Gilead's single tablet regimens for patients starting treatment for the first time alongside other non-STR based treatment options.[5]

Marketed HIV Therapies

Following is a summary of Gilead's HIV product portfolio, which includes three single tablet regimens – Stribild®, Eviplera®▼ and Atripla® – as well as component antiretroviral medicines that are used in combination with other therapies. Please visit **www.ema.europa.eu** for full product prescribing information, including Important Safety Information.

	Name	EU Approval	Contains	Antiretroviral Class
Single Tablet Regimens	**Stribild®** (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg)[6]	2013	4 compounds: • Elvitegravir • Cobicistat • Tenofovir disoproxil (as fumarate) (TDF) • Emtricitabine	• Integrase inhibitor • Pharmacoenhancing agent • Nucleotide reverse transcriptase inhibitor (NtRTI) • Nucleoside reverse transcriptase inhibitor (NRTI)
	Eviplera® (emtricitabine/ rilpivirine/tenofovir disoproxil)[7]	2011	3 compounds: • Rilpivirine • TDF • Emtricitabine	• Non-nucleoside reverse transcriptase inhibitor (NNRTI) • NtRTI • NRTI
	Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg)[8]	2007	3 compounds: • Efavirenz • TDF • Emtricitabine	• NNRTI • NtRTI • NRTI
Component Drugs	**Truvada®** (emtricitabine/ tenofovir disoproxil (as fumarate))[9]	2005	2 compounds: • TDF • Emtricitabine	• NtRTI • NRTI
	Emtriva® (emtricitabine)[10]	2003	1 compound: • Emtricitabine	• NRTI
	Viread® (tenofovir disoproxil (as fumarate))[11]	2002	1 compound: • TDF	• NtRTI

Expanding Treatment Access

Gilead recognises the urgent need for access to HIV medications worldwide, particularly in developing countries where the AIDS epidemic is significant. Gilead believes that the medicines it develops should be available to patients who need them regardless of their income or where they live, and has established innovative programmes and partnerships to expand global access to the company's therapies. These include licensing agreements with multiple drug manufacturers in India and South Africa that allow these companies to produce and distribute high-quality generic versions of Gilead's HIV therapies in 112 low- and middle-income countries. As a result of these efforts, 3.5 million people in the developing world are now benefiting from Gilead's HIV therapies. Gilead is also the first innovator pharmaceutical company to sign an agreement with the Medicines Patent Pool, an international non-profit organisation that expands access to medicines through the sharing of drug patents.

This fact sheet does not include all data contained in the Summary of Product Characteristics (SmPC) for Atripla, Emtriva, Eviplera, Stribild, Truvada or Viread. Please see the complete SmPCs for further details, available at www.ema.europa.eu.

For more information on Gilead Sciences, please visit the company's web site at www.gilead.com or call the Gilead Public Affairs Department at +44 (0)208 587 2349.

Sources

[1] Gilead Backgrounder on Treatment Expansion. May 2013. Available at: http://gilead.com/~/media/Files/pdfs/other/HIV-Access-Backgrounder.ashx

[2] Juday T et al. Factors associated with complete adherence to HIV combination antiretroviral therapy. *HIV Clin Trials*. 2011; Mar-Apr;12(2):71-8.

[3] Airoldi M et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. *Patient Preference Adherence.* 2010; 4:115-125.

[4] FDA Press Release. FDA approves new combination pill for HIV treatment for some patients. August 27, 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom

[5] European AIDS Clinical Society (EACS). *European Guidelines for Treatment of HIV Infected Adults in Europe: Version 6.1.* November 2012.

[6] Stribild SmPC. May 2013. Available at www.ema.europa.eu.

[7] Eviplera SmPC. February 2013. Available at www.ema.europa.eu.

[8] Atripla SmPC. January 2013. Available at www.ema.europa.eu.

[9] Truvada SmPC. February 2013. Available at www.ema.europa.eu.

[10] Emtriva SmPC. July 2011. Available at www.ema.europa.eu.

[11] Viread SmPC. November 2012. Available at www.ema.europa.eu.

HIV1/IHQ/12-12//1009 – May 2013